BUY Dr. Reddy's Laboratories Limited — Osho Krishan, Angel One
byOsho Krishan, Angel OneHorizon: NA (inferred Swing (≤2wk))4 Aug 2026via ET Now
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar. Fresenius Kabi will exclusively commercialize the product in the United States. This approval strengthens Dr. Redd
BSE · Company Update·1 Aug · 2w ago
Dr Reddy's Laboratories Ltd received approval for its gonorrhea drug from Thailand, following a US nod, as reported by Business Standard.
BSE · Company Update·28 Jul · 3w ago
Dr Reddy's ends distribution deal with Novartis India after ownership change
NewsCnbc-Tv18·7 Aug · 1w ago
Dr Reddy’s Srikakulam facility in Andhra Pradesh gets UFDA Form 483 with 3 observations
NewsCnbc-Tv18·30 Jul · 3w ago
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·22 Jul · 4w ago
Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss
NewsCnbc-Tv18·23 Jul · 4w ago
Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%
NewsCnbc-Tv18·23 Jul · 4w ago
Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%
NewsCnbc-Tv18·23 Jul · 4w ago
Dr Reddy's Q1 Results: Semaglutide API provision weighs on profit; margin halves
NewsCnbc-Tv18·22 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.